Lipoprotein (a) and anticardiolipin antibodies are risk factors for clinically relevant restenosis after elective balloon percutaneous transluminal coronary angioplasty

被引：19

作者：

Chiarugi, L ^{[1
]}

Prisco, D ^{[1
]}

Antonucci, E ^{[1
]}

Capanni, M ^{[1
]}

Fedi, S ^{[1
]}

Liotta, AA ^{[1
]}

Margheri, M ^{[1
]}

Simonetti, I ^{[1
]}

Gensini, FG ^{[1
]}

Abbate, R ^{[1
]}

机构：

[1] Univ Florence, Ist Clin Med Gen & Cardiol, I-50134 Florence, Italy

来源：

ATHEROSCLEROSIS | 2001年 / 154卷 / 01期

关键词：

Lp(a); anticardiolipin antibodies; fibrinolysis; PTCA; restenosis;

D O I：

10.1016/S0021-9150(00)00439-1

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Recent reports have shown the importance of new risk factors for cardiovascular disease. We investigated the relationship between Lp(a), fibrinolytic parameters and anticardiolipin antibodies (aCL) and the occurrence of clinical recurrence owing to restenosis after elective balloon percutaneous transluminal coronary angioplasty (PTCA) without stenting. In 167 patients, undergoing PTCA, Lp(a) plasma levels, aCL, euglobulin lysis time (ELT), plasminogen activator inhibitor-1 (PAI-1) activity and tissue-type plasminogen activator (t-PA) plasma levels were evaluated before the procedure. During follow-up 29 patients underwent clinical recurrence due to restenosis. Lp(a) levels were significantly higher in patients with restenosis in comparison to those without (P < 0.05); an earlier restenosis was observed in patients with Lp(a) values > 450 mg/L. Kaplan-Meier survival estimate showed an earlier occurrence of restenosis in patients with base-line Lp(a) > 300 mg/l associated with aCL positivity. High Lp(a) plasma levels play a role in the occurrence of clinical recurrence due to restenosis after elective balloon PTCA without stenting; the association with aCL accelerates the development of restenosis. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.

引用

页码：129 / 135

页数：7

共 50 条

[1] Lipoprotein(a) level does not predict restenosis after percutaneous transluminal coronary angioplasty [J].

Alaigh, P ;

Hoffman, CJ ;

Korlipara, G ;

Neuroth, A ;

Dervan, JP ;

Lawson, WE ;

Hultin, MB .

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1998, 18 (08) :1281-1286

[2]

*ANT ANT STROK STU, 1990, STROKE, V21, P1286

[3]

Atsumi T, 1998, J RHEUMATOL, V25, P69

[4] Antiphospholipid antibodies and pregnancy disorders in women with insulin dependent diabetes [J].

Boddi, M ;

Prisco, D ;

Fedi, S ;

Cellai, AP ;

Liotta, AA ;

Parretti, E ;

Mecacci, F ;

Mello, G .

THROMBOSIS RESEARCH, 1996, 82 (03) :207-216

[5] LP(A) CONCENTRATION AND APO(A) ISOFORM SIZE - RELATION TO THE PRESENCE OF CORONARY-ARTERY DISEASE IN FAMILIAL HYPERCHOLESTEROLEMIA [J].

BOWDEN, JF ;

PRITCHARD, PH ;

HILL, JS ;

FROHLICH, JJ .

ARTERIOSCLEROSIS AND THROMBOSIS, 1994, 14 (10) :1561-1568

[6]

BRANCH DW, 1990, BRIT J HAEMATOL, V74, P1

[7] UNSTABLE ANGINA - A CLASSIFICATION [J].

BRAUNWALD, E .

CIRCULATION, 1989, 80 (02) :410-414

[8] CARDIAC INVOLVEMENT IN PATIENTS WITH PRIMARY ANTIPHOSPHOLIPID SYNDROME [J].

BRENNER, B ;

BLUMENFELD, Z ;

MARKIEWICZ, W ;

REISNER, SA .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1991, 18 (04) :931-936

[9] QUANTITATIVE CORONARY ARTERIOGRAPHY - ESTIMATION OF DIMENSIONS, HEMODYNAMIC RESISTANCE, AND ATHEROMA MASS OF CORONARY-ARTERY LESIONS USING ARTERIOGRAM AND DIGITAL COMPUTATION [J].

BROWN, BG ;

BOLSON, E ;

FRIMER, M ;

DODGE, HT .

CIRCULATION, 1977, 55 (02) :329-337

[10]

Bussiere JL, 1996, ARCH MAL COEUR VAISS, V89, P425

← 1 2 3 4 5 →